Writing to your elected officials is the most direct way to influence the future of aging research and health policy in America. Right now, promising therapies that could prevent age-related disease or extend healthy years are trapped in outdated regulatory frameworks. By urging Congress to act, you’re helping unlock the full potential of science to improve lives, extend healthspan, and reduce long-term healthcare costs for all Americans.

National Institute for Healthy Longevity and Aging Research (NIHLAR)

By creating a dedicated NIH institute, we can centralize funding, standardize biomarker validation studies, and drive translational pipelines from lab to clinic. NIHLAR’s adoption of these recommendations unlocks targeted grant lines and ensures that breakthroughs in biological age measurement move swiftly into human studies.

(Read the full whitepaper → Call for a New National Institute…)

The Advanced Approval Pathway for Longevity Medicines (AAPLM)

Modernizing CLIA/CAP guidelines to accept validated surrogate biomarkers and harmonized assay protocols lets labs generate FDA-grade data more efficiently. AAPLM’s endorsement means trials can leverage non-animal “in silico” models and system-level endpoints, cutting development timelines and de-risking early-stage therapies.

(Read the full whitepaper → Advanced Approval Pathway for Longevity Medicines)

These initiatives provide the policy backbone—funding structures, lab standards, and regulatory pathways—that will accelerate new, age-modifying therapies and significantly expand human healthspan.